CASI Pharmaceuticals, Inc. (CASI) Financial Statements

Income statement

Metric	TTM	2024	2023	2022	2021
Revenue
Total Revenue	26.8M	28.5M	33.9M	43.1M	30.2M
Cost of Revenue	17.2M	17.4M	13.8M	15.8M	12.6M
Gross Profit	9.6M	11.1M	20.1M	27.3M	17.6M
Operating Expenses
R&D Expense	8.7M	8.9M	9.9M	16.0M	14.4M
SG&A Expense	44.4M	41.4M	41.8M	37.8M	38.4M
General & Admin Expense	25.8M	23.6M	25.4M	23.4M	23.7M
Selling & Marketing Expense	18.6M	17.9M	16.4M	14.3M	14.7M
Other Expenses	1.5M	407.0K	(6.6M)	—	6.3M
Total Operating Expenses	54.7M	50.8M	45.1M	53.8M	59.1M
Cost and Expenses	71.9M	68.2M	59.0M	69.6M	71.7M
Operating Income (EBIT)	(45.1M)	(39.6M)	(25.1M)	(26.5M)	(41.5M)
Non-Operating
Interest Income	132.0K	539.0K	614.0K	189.0K	321.0K
Interest Expense	636.0K	871.0K	—	62.0K	—
Net Interest Income	(504.0K)	(332.0K)	614.0K	127.0K	321.0K
Other Non-Op Income/Expense	(2.1M)	1.6M	(1.2M)	(11.8M)	5.7M
Non-Operating Income (excl Interest)	(2.6M)	(2.4M)	200.0K	—	(6.3M)
EBT (Pre-Tax Income)	(47.2M)	(38.1M)	(26.3M)	(38.3M)	(35.8M)
Income Tax Expense	2.2M	1.2M	(81.0K)	2.0M	—
Bottom Line
Net Income	(49.4M)	(39.3M)	(26.9M)	(41.0M)	(36.7M)
Earnings from Cont. Ops	(49.4M)	(39.3M)	(26.2M)	(40.3M)	(35.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(49.4M)	(39.3M)	(27.0M)	(41.0M)	(36.7M)
Per Share
Basic EPS	($3.16)	($2.56)	($2.02)	($3.01)	($2.69)
Diluted EPS	($3.16)	($2.56)	($2.02)	($3.01)	($2.69)
Revenue Per Share	$1.67	$1.86	$2.54	$3.16	$2.22
Shares
Basic Shares Outstanding	16.0M	15.3M	13.4M	13.6M	13.6M
Diluted Shares Outstanding	16.0M	15.3M	13.4M	13.6M	13.6M
Profitability Metrics
EBITDA	(41.4M)	(34.9M)	(21.5M)	(24.1M)	(33.4M)
D&A	1.2M	2.3M	3.7M	2.4M	1.8M
EBIT	(42.5M)	(37.2M)	(25.3M)	(26.5M)	(35.2M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025